Sagimet Biosciences Inc.

SGMT

Healthcare|Biotechnology|US

$9.85

+0.73 (+8.00%)

DCF Value

$1.05

Tangible Book / Share

$4.82

Cash / Share

$4.52

Next Earnings Report

Nov 12, 2026

EPS est. -$0.25 · Revenue est. $166.7K

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Oct 1, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Jan 2027

Est. completion

P1Acne

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

NCT06989840n=152

Aug 2027

Est. completion

P3Acne Vulgaris

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

NCT07863193n=800

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

May 2026

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

NCT05743621

Apr 2025

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

NCT03808558

Recent Press Releases

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 29, 2026 · GlobeNewsWire

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

Oct 22, 2026 · GlobeNewsWire

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

Oct 9, 2026 · GlobeNewsWire

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

Oct 1, 2026 · GlobeNewsWire

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

Sep 30, 2026 · GlobeNewsWire

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

Sep 30, 2026 · GlobeNewsWire

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

Sep 28, 2026 · GlobeNewsWire

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Sep 2, 2026 · GlobeNewsWire

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

Aug 25, 2026 · GlobeNewsWire

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 17, 2026 · GlobeNewsWire

SEC Filings (66)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 22, 2026	8-K	Material event	Document Index
Oct 7, 2026	SC 13G	Passive 5%+ stake	Document Index
Oct 1, 2026	8-K	Material event	Document Index
Oct 1, 2026	424B5	Offering prospectus	Document Index
Sep 30, 2026	8-K	Material event	Document Index
Sep 30, 2026	424B3	Offering prospectus	Document Index
Aug 14, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 13, 2026	8-K	Material event	Document Index
Aug 11, 2026	8-K	Material event	Document Index
Aug 11, 2026	10-Q	Quarterly report	Document Index
Jul 30, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 21, 2026	8-K	Material event	Document Index
Jun 12, 2026	8-K	Material event	Document Index
May 12, 2026	8-K	Material event	Document Index
May 12, 2026	10-Q	Quarterly report	Document Index
Apr 28, 2026	8-K	Material event	Document Index
Apr 28, 2026	424B5	Offering prospectus	Document Index
Apr 27, 2026	8-K	Material event	Document Index
Apr 27, 2026	8-K	Material event	Document Index
Apr 21, 2026	ARS	Annual report to holders	Document Index
Apr 21, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Apr 21, 2026	8-K	Material event	Document Index
Mar 11, 2026	S-8	Employee stock plan	Document Index
Mar 11, 2026	S-8	Employee stock plan	Document Index
Mar 11, 2026	8-K	Material event	Document Index
Mar 11, 2026	10-K	Annual report	Document Index
Feb 2, 2026	8-K	Material event	Document Index
Dec 18, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Dec 18, 2025	8-K	Material event	Document Index
Dec 17, 2025	8-K	Material event	Document Index
Nov 14, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Nov 13, 2025	8-K	Material event	Document Index
Nov 13, 2025	10-Q	Quarterly report	Document Index
Oct 23, 2025	8-K	Material event	Document Index
Aug 22, 2025	8-K	Material event	Document Index
Aug 14, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Aug 14, 2025	8-K	Material event	Document Index
Aug 14, 2025	424B5	Offering prospectus	Document Index
Aug 14, 2025	SC 13G	Passive 5%+ stake	Document Index
Aug 13, 2025	8-K	Material event	Document Index